Kornimate/medical-research-clean huggingface dataset:
the asia primary tube versus trab (tvt) study

Conditions: Glaucoma

Summary: comparison of ahmed glaucoma implant (agi) against trabeculectomy with mitomycin c in patients with uncontrolled open angle glaucoma

the objective of the asia primary tube versus trab (tvt) study is to compare the efficacy and safety of placement of an ahmed glaucoma implant (agi) (new world medical inc., rancho cucamonga, ca, usa) against trabeculectomy with mitomycin c in patients with uncontrolled glaucoma, who may or may not have had previous clear corneal cataract surgery with intraocular lens implantation, over 5 years. outcome discrimination between the two treatment groups will be made using following parameters: 1. intraocular pressure 2. need for supplemental medical therapy 3. incidence of short and long term surgical complications and need for re-operation. 4. visual function (visual acuity and visual field) hypothesis: glaucoma drainage implants have better surgical outcomes in terms of iop lowering efficacy compared to trabeculectomy with mitomycin-c over 5 years in asian patients with medically uncontrolled glaucoma.

Eligibility criteria:
inclusion criteria: 1. open angle glaucoma including primary open angle glaucoma, pseudoexfoliative or pigmentary glaucoma. 2. iop \> 18 mm hg on 2 or more medications on at least 2 visits 3. informed consent given and consent form signed. exclusion criteria: 1. unwilling or unable to give consent, unwilling to accept randomisation, or unable to return for scheduled protocol visits. 2. pregnant or nursing women 3. no light perception vision 4. previous incisional intraocular surgery, other than uncomplicated clear corneal cataract surgery 5. previous ocular laser in study eye (keratorefractive surgery and cyclodestructive procedure), except for laser trabeculoplasty procedures (argon laser and selective laser trabeculoplasty) 6. iris neovascularisation or proliferative retinopathy 7. primary angle closure or primary angle closure glaucoma 8. iridocorneal endothelial syndrome or anterior segment dysgenesis 9. epithelial or fibrous downgrowth 10. aphakia 11. chronic or recurrent uveitis 12. severe posterior blepharitis 13. unwilling to discontinue contact lens use after surgery 14. glaucoma secondary to penetrating keratoplasty, trauma, steroids, retinal disease/surgery or neovascular disease 15. conjunctival scarring from prior ocular surgery, trauma or cicatrizing disease precluding a superior trabeculectomy 16. need for glaucoma surgery combined with other ocular procedures (i.e. cataract surgery, penetrating keratoplasty, or retinal surgery) or anticipated need for urgent additional ocular surgery 17. advanced glaucoma with md \<-20db
screening for hepatitis b, hepatitis c and aids viruses using dried blood spot

Conditions: Hepatitis B; Hepatitis C; AIDS

Summary: the aim of the study is to screen for hepatitis b, hepatitis c and aids viruses using a dried blood spot in drug users


Eligibility criteria:
inclusion criteria: * former or active intravenous and/or nasal drug user * person on opiate substitution therapy exclusion criteria: * person with known active viral infection(s)

Keywords: dried blood spot
urinary congophilia as an indicator of activity of lupus nephritis

Conditions: Lupus Nephritis (LN)

Summary: evaluation of the impact of sle on urinary levels of congophilia and their relationship to renal histopathology and activity of lupus nephritis (ln)

systemic lupus erythematosus (sle) is an inflammatory autoimmune disease that can affect all body organs. the reported lifetime incidence of lupus nephritis (ln) in sle patients is 20%- 60% and it is histologically evident in most sle patients, even without clinical manifestations of kidney disease . lupus nephritis is associated with higher mortality , as within 5 years of diagnosis, between 10 and 30 percent of these people develop end-stage renal disease . early detection and treatment of lupus nephritis can significantly improve renal outcomes and decrease overall mortality . endoplasmic reticulum (er) stress proteins, which act as protein quality control factors in the secretory pathway in the cell are induced by er stress in inflammatory lesions, and also participate in autoimmunity and inflammation processes, er stress proteins are expressed not only in the er but also occasionally at the cell surface that plays pathophysiological roles in autoimmune and inflammatory diseases as pro- or anti-inflammatory factors, protein folding is easily impaired (misfolding) by different cytotoxic stresses as inflammation or hypoxia , that may contribute to disease pathogenesis by either reducing the biological activity of the protein or due to toxicity by the misfolded proteins, the detection of the abnormally misfolded proteins using the congo red stain is referred to as congophilia, urinary congophilia was assessed by congo red dot blot (crdb) assay congo red is a synthetic diazo dye with specific affinity for β-sheets of amyloid fibrils of misfolded proteins, in addition to the simplicity of congophilia based dot blot technique, the non-invasiveness of the method is useful in adapting the crdb assay for self-collected urine samples. one previous study in pregnant females with lupus nephritis said that urinary congophilia has a diagnostic value in patients with lupus nephritis and can be used as a reliable marker of disease activity as the presence of urinary congophilia biomarker is related to disease activity rather than pregnancy.

Eligibility criteria:
inclusion criteria: - adult patients ≥ 18 years old that were diagnosed with sle according to eular/acr classification criteria 2019 for sle, and lupus nephritis based on renal biopsy or active urinary sediment (proteinuria or hematuria ) exclusion criteria: * any patient has evidence of nephritis that may cause proteinuria as diabetes mellitus and any other causes of glomerulonephritis other than lupus nephritis * pregnant females with lupus nephritis and hypertensive disorders

Keywords: congophilia lupus nephritis congo red
premature discontinuation of contraceptive implants

Conditions: Contraception Behavior

Summary: to compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (cocs) and a bleeding rescue regimen (cocr intervention) to participants given standard counseling (comparator).

objective: to compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (cocs) and a bleeding rescue regimen (cocr intervention) to participants given standard counseling (comparator). secondary objectives: to determine if participants initiating the contraceptive implant who are also provided cocr are more likely than participants receiving standard counseling to: 1. report higher levels of satisfaction with their contraceptive implant at one year following initiation 2. require less clinical follow-up and clinical resources in the year following initiation.

Eligibility criteria:
inclusion criteria: 1. you are between ages of 14 to 22.9 years. 2. started etonogestrel implant for the first time and have never used the implant before. exclusion criteria: 1. there is any contraindication to estrogen containing birth control. 2. desire of pregnancy in next 12 months. 3. plans to move from the area in next 12 months and is not able to come to the clinic.
emr data to assess monitoring of patients treated with quetiapine

Conditions: Schizophrenia; Bipolar Disorder; Major Depressive Disorder

Summary: a study to evaluate the effectiveness of an update of educational materials with respect to evaluation of monitoring of metabolic parameters

objective assessment of metabolic monitoring in patients treated with seroquel® or seroquel® xr/quetiapine fumarate: use of ims disease analyzer to assess physician behaviour in the uk and germany

Eligibility criteria:
inclusion criteria: - electronic medical records of patients with diagnoses of schizophrenia, bipolar disorder (bpd) or major depressive disorder (mdd) treated with seroquel® or seroquel®xr during the calendar periods: 13 feb - 31 aug 2012 seen by gp \& psychiatrists in germany \& 11 jan-31 july 2012 seen by gps in the uk exclusion criteria: - patients with above mentioned diagnoses treated with seroquel® or seroquel® xr/quetiapine fumarate not having any medical encounters during the time periods: 13 feb - 31 aug 2012 in germany \& 11 jan-31 july 2012 by gps in the uk

Keywords: effectiveness of risk minimization metabolic monitoring seroquel® or seroquel® xr/quetiapine fumarate
assessment of oral caffeine intake in changing the severity of acute migraine attack using vas score among patients attending headache and neurology outpatients clinic of ainshams university hospitals

Conditions: Migraine; Migraine Disease; Migraine Headache; Migraine Headache, With or Without Aura; Migraine, Acute

Summary: caffeine extracted from green tea to abort acute attack of migraine

caffeine tablets extracted from green tea can be used as caffeinated drinks to decrease intensity of migraine attacks

Eligibility criteria:
inclusion criteria: patients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ichd-3 diagnosis will be legible for the study. exclusion criteria: patients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study patients who had headache due to: cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded
a study of belimumab administered subcutaneously in subjects with systemic lupus erythematosus (sle)

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (sc) to adult subjects with systemic lupus erythematosus (sle).

this is a phase 3, multi-center, international, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (sc) (200 mg weekly) in adult subjects with active systemic lupus erythematosus (sle). approximately 816 sle subjects will be randomized, with a target of about 544 subjects receiving belimumab and 272 subjects receiving placebo. subjects completing the 52-week double-blind period can enter a 6-month open-label extension in which all subjects receive belimumab 200 mg sc weekly.

Eligibility criteria:
inclusion criteria: 1. at least 18 years of age. 2. clinical diagnosis of systemic lupus erythematosus (sle) by acr criteria. 3. active sle disease. 4. autoantibody-positive. 5. on stable sle treatment regimen which may include corticosteroids (for example, prednisone), antimalarial (for example, hydroxychloroquine) and/or immunosuppressants (for example, azathioprine, methotrexate, mycophenolate, etc.) exclusion criteria: 1. pregnant or nursing. 2. have received treatment with any b cell targeted therapy (for example, rituximab or belimumab). 3. have received treatment an investigational biological agent in the past year. 4. have received intravenous (iv) cyclophosphamide within 90 days of day 0. 5. have severe active lupus kidney disease. 6. have severe active central nervous system (cns) lupus. 7. have required management of acute or chronic infections within the past 60 days. 8. have current drug or alcohol abuse or dependence. 9. have a positive test for human immunodeficiency virus (hiv), hepatitis b, or hepatitis c. 10. have a history of hypersensitivity reactions to contrast agents or biological medicines.

Keywords: subcutaneous lupus systemic lupus erythematosus sle belimumab autoimmune disease antibodies
maribavir versus oral ganciclovir for the prevention of cytomegalovirus (cmv) disease in liver transplant recipients

Conditions: Cytomegalovirus Infections

Summary: the purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing cmv disease when administered for up to 14 weeks in patients who have had a liver transplant.

cytomegalovirus (cmv) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. maribavir is a new oral anti-cmv drug with a novel mechanism of action compared to currently available anti-cmv drugs. this study will test the safety and efficacy of maribavir for the prevention of cmv disease when given as prophylaxis for up to 14 weeks following orthotopic liver transplantation.

Eligibility criteria:
inclusion criteria: * orthotopic liver transplant recipient * donor cmv seropositive / recipient cmv seronegative * enrolled within 10 days after liver transplant * able to swallow tablets exclusion criteria: * multiple organ transplant * hiv infection * cmv disease * use of other anti-cmv therapy at time of enrollment

Keywords: cytomegalovirus cmv prophylaxis liver liver transplant
quality of cardiopulmonary resuscitation without and with defibrillator feedback

Conditions: Cardiac Arrest

Summary: quality of bystander cardiopulmonary resuscitation (cpr) affect patient survival. quality of professional cpr on patients has not been studied in detail, but it is regularly reported that the quality when tested on manikins deteriorates dramatically within months after training. automated direct feedback on cpr quality from manikins brings quality back within a couple of minutes. similar feedback has been incorporated into a defibrillator which also monitors quality of cpr. we hypothesise that quality of professional clinical cpr improves with such feedback

defibrillators which monitor quality of cpr via changes in thoracic impedance (for ventilation) and movement of the sternum employing an accelerometer (for chest compressions) will be employed in ambulances in akershus county (norway), stockholm (sweden) and london (uk). during phase 1 quality of cpr will be monitored without feedback from the defibrillator. during phase 2 the ambulance personnel will receive feedback via the defibrillator. during phase 3 the ambulance personnel will be retrained with particular attention to the quality problems that became apparent in phase 3. quality of cpr will be continuously recorded by the defibrillators and the data collected and sent via internet to laerdal medical. all other cardiac arrest data including survival will be recorded using standard datasets for cardiac arrest research as developed by a task force with members from the organisations in international liaison committee on resuscitation (utstein guidelines). the data will be annotated and analyzed in detail by researchers at university of oslo

Eligibility criteria:
inclusion criteria: * cardiac arrest out-of-hospital exclusion criteria: * \< 18 years old

Keywords: cardiac arrest resuscitation quality feedback training
efficacy of collagen sponge versus collagen membrane on ridge preservation of periodontally compromised teeth

Conditions: Periodontitis

Summary: the study aims to evaluate the efficacy of ridge preservation with collagen sponge or collagen membrane in combination with collagenated bovine bone mineral in extraction sockets of periodontally diseased teeth.

the study aims to evaluate the changes of clinical and radiographic outcomes following ridge preservation with collagen sponge or collagen membrane in combination with collagenated bovine bone mineral in extraction sockets of periodontally diseased teeth. the included patients will be randomized into two groups. the patients in control group will be treated with collagen membrane + collagenated bovine bone mineral, and those in the test group will be treated with collagen sponge + collagenated bovine bone mineral. the horizontal width of ridge, the vertical height of ridge at the buccal and palatal/lingual plates, width of keratinized tissue and thickness of mucosa will be measured before surgery and at 6 months postoperatively.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. need for molar extraction due to periodontal disease and plan for late implantation 3. no acute infection, such as abscess or effusion 4. presence of bone defects on at one or two socket walls, where the height of the horizontal (suprabony) component of the defect (alveolar bone crest - cement-enamel junction) is \>50% of the corresponding root length and the bone height of socket walls is at least 3 mm 5. presence of one adjacent tooth to the extraction site exclusion criteria: 1. smoking 2. pregnancy or lactation 3. untreated periodontal disease 4. severe systemic conditions that contraindicate surgery (such as diabetes, heart disease, cancer etc.) 5. under radiotherapy 6. systemic disease or medication that influences bone metabolism and mucosal healing (such as immunosuppressants, phenytoin, bisphosphonates etc.) 7. extraction of multiple adjacent teeth 8. allergy to any of the materials used in the study
relevance of recording an ecg trace with a connected watch

Conditions: Arrhythmias, Cardiac

Summary: over the past few years, various systems have been developed to record ecg traces on an ambulatory basis. the latest connected watch models feature 2-electrode ecg recording. this single (1d) or six derivations (6d) can be used to derive a wealth of information about the heart's rhythm. the information that can be derived from an ecg recording with a derivation goes far beyond̀ simple differentiation between atrial fibrillation and sinus rhythm. in contrast, in various clinical situations, a tracing restricted to an intracardiac defibrillator (icd) may prove falsely normal, wrongly reassuring a patient and delaying management. the primary objective of the study is to evaluate the sensitivity of ecg-1d or 6d recordings from a connected watch in measuring electrical parameters, compared with a standard ecg-12d, also to obtain a bank of tracings, to create and validate an artificial intelligence algorithm for the automatic analysis of ecg tracings recorded with a connected watch and also to validate the feasibility and sensitivity of recording an ecg tracing with a connected watch in children.

single-arm prospective study to evaluate the measurement of electrocardiographic parameters obtained using two non-invasive ecg methods, one 12-lead reference method and the second 1 or 6 leads recorded from a connected watch, in a group of patients with healthy hearts (normal ecg) and 19 pathological groups.

Eligibility criteria:
inclusion criteria: * patients hospitalized or seen in consultation in one of the departments of the haut lévêque cardiology hospital, * patient of both sexes, minor (from birth to 18 years) or adult, * free, informed and written consent from the patient or, in the case of minors, from the legal parent (at the latest on the day of inclusion and before any examination required for the research), * subject affiliated to or benefiting from a social security regime. exclusion criteria: * person incapable of giving consent, * person subject to a legal protection measure (safeguard of justice, tutorship or curatorship), * a person deprived of liberty by judicial or administrative decision.

Keywords: electrocardiogram smart watch arrhythmia artificial intelligent remote monitoring
the pharmacokinetics and safety of idv/r with nrtis in hiv/tb co-infected patients receiving rifampicin

Conditions: HIV Infections; Tuberculosis

Summary: we believe that there is a strong rationale for the study of idv/r 600/100 bid as a boosted-pi combination that, in the presence of rmp, is able to produce a satisfactory pk profile associated with adequate antiretroviral potency, tolerability and efficacy.

the fixed-dose combination of d4t+3tc+nvp (gpovir) has been widely used in thailand since june 2002. the prevalence of nnrti resistance has increased since 2005. efavirenz-based antiretroviral therapy (art) is preferred in patients with tb/hiv receiving rifampin-containing tb regimens. however, efavirenz cannot be used in the context of nnrti failure, intolerance or toxicity. the optimal art in populations receiving rifampicin remains unknown. rifabutin, which is recommended in combination with a boosted protease inhibitor (pi/r) is expensive and not available in thailand and other developing countries. ritonavir-boosted indinavir (idv/r) is potent and the cheapest boosted pi available in thailand. if idv/r in combination with rifampin demonstrates suitable pharmacokinetics and is well tolerated, this regimen might prove useful and could be widely implemented. however, high rates of gastrointestinal and renal toxicity have been demonstrated in thai patients receiving standard doses of idv/r 800/100 bid. we believe that there is a strong rationale to study if idv/r 600/100 bid in combination with rifampin is able to produce a satisfactory pharmacokinetic profile, with antiretroviral potency, tolerability and efficacy.

Eligibility criteria:
inclusion criteria: * confirmed hiv positive after voluntary counselling and testing * aged between 18 and 60 years of age * antiretroviral treatment naive * cd4+ cell count of \<200 cells/mm3 at the time of tb diagnosis * alt \<5 times uln * serum creatinine \<1.4 mg/dl * haemoglobin \>8 mg/l * tb diagnosis; either probable (clinical symptoms plus chest x-ray and response to anti-tb medication) or definitive( sputum afb culture confirmed) and receiving or planning to receive rifampicin-containing anti-tb therapy for at least a 2 week period before the initiation of art * no other active oi (cdc class c event) * able to provide written informed consent exclusion criteria: * current use of steroids and other immunosuppressive agents * current use of any prohibited medications related to compliance and drug pharmacokinetics * patients with current alcohol or illicit substance use that in the opinion of the site principal investigator would conflict with any aspect of the conduct of the trial. * previous exposure to nevirapine monotherapy * unlikely to be able to remain in follow-up for the protocol defined period * patients with proven or suspected acute hepatitis. patients with chronic viral hepatitis are eligible provided alt, ast \< 5 x uln. * karnofsky performance score \<30%

Keywords: indinavir/ritonavir hiv/tb rifampicin pk and efficacy of idv/rtv 600/100 mg bid with rifampicin treatment naive
brief online intervention for chronic pain

Conditions: Chronic Pain

Summary: the purpose of this study is to explore the effects of writing about chronic pain on mental and physical health. the effectiveness of two different types of brief online writing interventions will be explored in individuals with chronic pain.

chronic pain is highly prevalent and costly, but often not treated effectively. psychological interventions are needed as part of chronic pain treatment since the pain affects many aspects of an individual's life. in particular, brief psychological interventions that are easily accessible (i.e., online) could benefit many people with chronic pain. writing interventions have been used in recent years to understand difficult experiences. writing interventions have been found to help individuals explore distressing thoughts and feelings, such as those that are associated with pain.

Eligibility criteria:
inclusion criteria: * diagnosed with chronic pain or a chronic pain condition or discussed pain management strategies (e.g., pain medication) with a doctor * experience pain on most days of the month for at least six months * able to read and write in english exclusion criteria: * chronic pain directly caused by a terminal condition (e.g., stage 4 cancer)

Keywords: chronic pain psychological adjustment writing brief intervention online internet interventions